USPTO Patent Grant: Bispecific Antibodies Targeting CD47 and PD-L1

ChangeBridge: Patent Grants - Peptides (C07K)

Published March 24th, 2026

Detected March 25th, 2026

Summary

The USPTO has granted patent US12583922B2 for bispecific antibodies targeting CD47 and PD-L1. The patent, assigned to Novimmune SA, covers methods of making and using these antibodies for treating cancers associated with malignant cells expressing CD47 and/or PD-L1.

View original document View source feed page

What changed

The United States Patent and Trademark Office (USPTO) has issued patent US12583922B2, covering bispecific antibodies designed to target both CD47 and Programmed Death-Ligand 1 (PD-L1). The patent, assigned to Novimmune SA, includes claims related to the creation of these antibodies, the nucleic acids encoding them, and their therapeutic application in treating conditions involving malignant cells that express CD47 and/or PD-L1.

This patent grant signifies a new intellectual property right for Novimmune SA in the field of immuno-oncology. While patent grants are non-binding regulatory instruments, they can influence market exclusivity and R&D strategies for pharmaceutical and biotechnology companies. Companies operating in this space should be aware of this granted patent and its claims to ensure freedom to operate and to inform their own research and development efforts in similar therapeutic areas.

Source document (simplified)

← USPTO Patent Grants

Bispecific antibodies targeting CD47 and PD-L1 and methods of use thereof

Grant US12583922B2 Kind: B2 Mar 24, 2026

Assignee

Novimmune SA

Inventors

Xavier Chauchet, Krzysztof Masternak, Limin Shang, Elise Penarrieta, Walter Ferlin

Abstract

This disclosure provides bispecific antibodies that specifically bind to CD47 and Programmed Death-Ligand 1 (PD-L1). The disclosure further relates to methods of making the bispecific antibodies and nucleic acids encoding the antibodies. The disclosure further relates to therapeutic methods for use of the bispecific antibodies in the treatment of a condition associated with malignant cells expressing CD47 and/or PD-L1.